Aydillo, Teresa http://orcid.org/0000-0003-3086-1058
Gonzalez-Reiche, Ana S. http://orcid.org/0000-0003-3583-4497
Stadlbauer, Daniel http://orcid.org/0000-0001-6792-7650
Amper, Mary Anne http://orcid.org/0000-0001-5477-1933
Nair, Venugopalan D. http://orcid.org/0000-0002-8231-6230
Mariottini, Chiara
Sealfon, Stuart C. http://orcid.org/0000-0001-5791-1217
van Bakel, Harm http://orcid.org/0000-0002-1376-6916
Palese, Peter http://orcid.org/0000-0002-0337-5823
Krammer, Florian http://orcid.org/0000-0003-4121-776X
GarcĂa-Sastre, Adolfo http://orcid.org/0000-0002-6551-1827
Article History
Received: 11 April 2022
Accepted: 25 November 2022
First Online: 10 December 2022
Competing interests
: The Icahn School of Medicine at Mount Sinai (ISMMS) has issued patents and filed patent applications covering the use of chimeric hemagglutinin antigens as vaccines. A.G.-S., P.P., and F.K. are named as inventors on these patents and applications. The ISMMS and the inventors have received payments as consideration for these rights. The laboratories of A.G.-S., P.P., and F.K. were also engaged in a research program that was funded by GlaxoSmithKline Biologicals SA. All other authors declare no competing interests. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary and Pfizer, outside of the reported work.